Browse MARCO

Summary
SymbolMARCO
Namemacrophage receptor with collagenous structure
Aliases SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location2q14.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type II membrane protein
Domain PF01391 Collagen triple helix repeat (20 copies)
PF00530 Scavenger receptor cysteine-rich domain
Function

Pattern recognition receptor (PRR) which binds Gram-positive and Gram-negative bacteria (PubMed:9468508). Also plays a role in binding of unopsonized particles by alveolar macrophages (By similarity). Binds to the secretoglobin SCGB3A2 (PubMed:12847263).

> Gene Ontology
 
Biological Process GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0006898 receptor-mediated endocytosis
GO:0006909 phagocytosis
GO:0031349 positive regulation of defense response
GO:0043277 apoptotic cell clearance
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
Molecular Function GO:0005044 scavenger receptor activity
GO:0008329 signaling pattern recognition receptor activity
GO:0038024 cargo receptor activity
GO:0038187 pattern recognition receptor activity
Cellular Component GO:0005581 collagen trimer
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030666 endocytic vesicle membrane
> KEGG and Reactome Pathway
 
KEGG hsa04145 Phagosome
Reactome R-HSA-2173782: Binding and Uptake of Ligands by Scavenger Receptors
R-HSA-3000480: Scavenging by Class A Receptors
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolMARCO
Namemacrophage receptor with collagenous structure
Aliases SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location2q14.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MARCO and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between MARCO and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29667169lung carcinomaPromote immunity (infiltration)On the transcriptomic level, we found a positive association between MARCO gene expression and general immune response pathways including strong links to immunosuppressive TAMs, T-cell infiltration and immune checkpoint molecules.
Summary
SymbolMARCO
Namemacrophage receptor with collagenous structure
Aliases SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location2q14.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MARCO in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMARCO
Namemacrophage receptor with collagenous structure
Aliases SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location2q14.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MARCO in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3820.524
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.2320.428
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2630.778
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4410.509
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9720.511
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2270.896
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0980.897
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6510.624
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5350.712
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8790.604
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.860.418
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3470.349
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MARCO in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.12.78.40.12
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.13.47.70.176
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21171923.5-4.51
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)862516.78.31
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.427.3-11.90.63
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382710.57.43.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMARCO
Namemacrophage receptor with collagenous structure
Aliases SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location2q14.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MARCO. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMARCO
Namemacrophage receptor with collagenous structure
Aliases SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location2q14.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MARCO. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MARCO.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMARCO
Namemacrophage receptor with collagenous structure
Aliases SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location2q14.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MARCO. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMARCO
Namemacrophage receptor with collagenous structure
Aliases SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location2q14.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MARCO expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMARCO
Namemacrophage receptor with collagenous structure
Aliases SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location2q14.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MARCO and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMARCO
Namemacrophage receptor with collagenous structure
Aliases SCARA2; scavenger receptor class A, member 2; Scavenger receptor class A member 2; Macrophage receptor MARCO
Chromosomal Location2q14.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MARCO collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MARCO.
ID Name Drug Type Targets #Targets
DB09536Titanium dioxideSmall MoleculeMARCO1
DB11132Silicon dioxideSmall MoleculeMARCO1